Clinical trials
Myasthenia Gravis trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
51 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 6 |
| 2020 | 2 |
| 2021 | 7 |
| 2022 | 2 |
| 2024 | 12 |
| 2025 | 8 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Recruiting | 14 |
| Active, not recruiting | 11 |
| Enrolling by invitation | 2 |
| Not yet recruiting | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| argenx | 8 |
| Centre Hospitalier Universitaire de Nice | 5 |
| Alexion Pharmaceuticals, Inc. | 4 |
| Assistance Publique - Hôpitaux de Paris | 4 |
| UCB Biopharma SRL | 4 |
| Novartis Pharmaceuticals | 3 |
| Amgen | 2 |
| Fondation Ophtalmologique Adolphe de Rothschild | 2 |
| Grifols Therapeutics LLC | 2 |
| Hoffmann-La Roche | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myasthenia Gravis | 51 |
| Atypical Hemolytic Uremic Syndrome | 1 |
| COVID-19 | 1 |
| Dyspnea | 1 |
| Fatigue | 1 |
| Guillain-Barre Syndrome | 1 |
| Hemoglobinuria, Paroxysmal | 1 |
| Lambert-Eaton Myasthenic Syndrome | 1 |
| Multiple Sclerosis | 1 |
| Myasthenic Syndromes, Congenital | 1 |
Trials
Showing 76 to 51 of 51. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.